NASDAQ:OABI OmniAb (OABI) Stock Price, News & Analysis $1.80 +0.04 (+2.27%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$1.78 -0.02 (-1.11%) As of 04/28/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OmniAb Stock (NASDAQ:OABI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OmniAb alerts:Sign Up Key Stats Today's Range$1.75▼$1.8250-Day Range$1.76▼$3.8852-Week Range$1.70▼$4.96Volume1.12 million shsAverage Volume580,269 shsMarket Capitalization$219.84 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewOmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.Read More… OmniAb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreOABI MarketRank™: OmniAb scored higher than 54% of companies evaluated by MarketBeat, and ranked 367th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOmniAb has only been the subject of 3 research reports in the past 90 days.Read more about OmniAb's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OmniAb are expected to grow in the coming year, from ($0.61) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OmniAb is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OmniAb is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOmniAb has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OmniAb's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.86% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently decreased by 4.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOmniAb does not currently pay a dividend.Dividend GrowthOmniAb does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.86% of the float of OmniAb has been sold short.Short Interest Ratio / Days to CoverOmniAb has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in OmniAb has recently decreased by 4.52%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.75 News SentimentOmniAb has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OmniAb this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OmniAb insiders have bought 55.72% more of their company's stock than they have sold. Specifically, they have bought $295,512.00 in company stock and sold $189,773.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of OmniAb is held by insiders.Percentage Held by Institutions72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OmniAb's insider trading history. Receive OABI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter. Email Address OABI Stock News HeadlinesKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 29, 2025 | Paradigm Press (Ad)OmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comQ1 Earnings Forecast for OmniAb Issued By Leerink PartnrsApril 20, 2025 | americanbankingnews.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comSee More Headlines OABI Stock Analysis - Frequently Asked Questions How have OABI shares performed this year? OmniAb's stock was trading at $3.54 at the start of the year. Since then, OABI stock has decreased by 49.2% and is now trading at $1.80. View the best growth stocks for 2025 here. How were OmniAb's earnings last quarter? OmniAb, Inc. (NASDAQ:OABI) announced its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The business earned $10.80 million during the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative trailing twelve-month return on equity of 20.97%. Read the conference call transcript. Who are OmniAb's major shareholders? OmniAb's top institutional investors include Chicago Capital LLC (2.15%), Villere ST Denis J & Co. LLC (1.18%) and Woodstock Corp (0.61%). Insiders that own company stock include Charles S Berkman and Jennifer R Cochran. View institutional ownership trends. How do I buy shares of OmniAb? Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OmniAb own? Based on aggregate information from My MarketBeat watchlists, some other companies that OmniAb investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings3/18/2025Today4/28/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:OABI CIK1846253 Webwww.omniab.com Phone510-250-7800FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+288.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,620,000.00 Net Margins-308.78% Pretax Margin-373.44% Return on Equity-20.97% Return on Assets-18.05% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.62 Sales & Book Value Annual Sales$26.39 million Price / Sales8.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book0.67Miscellaneous Outstanding Shares122,135,000Free Float129,071,000Market Cap$219.84 million OptionableOptionable Beta0.06 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:OABI) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OmniAb, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OmniAb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.